SCHEMBL1930591

SCHEMBL1930591

CCc1ccc(Nc2nnc(Cc3ccnc(O)c3)c3ccccc23)cc1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.53
FLT1 P17948 14/20 0.53
PDGFRB P09619 12/20 0.51
KIT P10721 11/20 0.51
CSF1R P07333 2/20 0.46
FLT4 P35916 2/20 0.46
CIT O14578 1/20 0.46
EGFR P00533 1/20 0.46
HLA-A P04439 1/20 0.46
RET P07949 1/20 0.46
PDGFRA P16234 1/20 0.46
RPS6KB1 P23443 1/20 0.46
FRK P42685 1/20 0.46
CDK8 P49336 1/20 0.46
DDR1 Q08345 1/20 0.46
STK3 Q13188 1/20 0.46
PTK6 Q13882 1/20 0.46
MAP3K19 Q56UN5 1/20 0.46
CDK19 Q9BWU1 1/20 0.46
MAP3K20 Q9NYL2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12201973 0.87 KDR (0.65) KDRFLT1PDGFRBKITCSF1R
SCHEMBL1929579 0.87 KDR (0.52) KDRFLT1PDGFRBKITCSF1R
SCHEMBL1386144 0.80 NR3C2 (0.34) KDRFLT1PDGFRBKITEGFR
SCHEMBL12201975 0.78 KDR (0.47) KDRFLT1PDGFRBKIT
SCHEMBL1652070 0.74 KDR (0.71) KDRFLT1PDGFRBKITCSF1R
SCHEMBL29365850 0.74 KDR (0.71) KDRFLT1PDGFRBKITCSF1R
SCHEMBL6598729 0.72 KDR (0.53) KDRFLT1PDGFRBKITCSF1R
SCHEMBL14221880 0.72 KDR (0.44) KDRFLT1PDGFRBKITCSF1R
SCHEMBL13955593 0.72 FLT1 (0.43) KDRFLT1PDGFRBKITCSF1R
SCHEMBL6503289 0.72 KDR (0.70) KDRFLT1PDGFRBKITCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7399761-B2 Phthalazine derivatives with angiogenesis inhibiting activity NOVARTIS AG (CH) 2008-07-15 US claimed
EP-1387836-B1 PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY NOVARTIS AG (CH) 2008-04-23 EP claimed
EP-1387836-A1 PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY Novartis AG (CH) 2004-02-11 EP claimed
WO-2002090346-A1 PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY NOVARTIS AG (CH) 2002-11-14 WO claimed
US-8034814-B2 Phthalazine derivatives with angiogenesis inhibiting activity NOVARTIS AG (CH) 2011-10-11 US disclosed
US-20110130399-A1 Phthalazine Derivatives with Angiogenesis Inhibiting Activity NOVARTIS AG (CH) 2011-06-02 US disclosed
US-20090076003-A1 Phthalazine Derivatives with Angiogenesis Inhibiting Activity NOVARTIS AG 2009-03-19 US disclosed
EP-1387836-B1 PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY NOVARTIS AG (CH) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076003-A1 Phthalazine Derivatives with Angiogenesis Inhibiting Activity KDR, FLT1, FLT4 KDR 1/4885FLT1 2/4885PDGFRB 24/4885
US-20110130399-A1 Phthalazine Derivatives with Angiogenesis Inhibiting Activity KDR, FLT1, FLT4 KDR 1/4885FLT1 2/4885PDGFRB 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.